Dallas, Texas 04/14/2014 (FINANCIALSTRENDS) – Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), the leading biotechnology company with integrated commercial as well as drug development operations has a primary focus in two types of diseases- hematology as well as oncology.
Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), according to analysts in the first week of April has received analyst coverage. Experts suggest that the overall operating cash flow as well as the poor growth in the earnings per share.
Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), according to analysts has reported marginal decline in cash flow to the tune of $7.92 million or 2.18%, in comparison to the past quarter of the previous year.
The fact that Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) is performing well below industry standard does hit a few odd notes, resulting in loss in investor sentiment.
Solutions which matter
Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) currently in the US markets three types of oncology drugs. These include – Fusilev, Folotyn as well as Zevalin. Only the last of these drugs, Zevalin, is sold in the US. Additionally, two other drugs- Apaziquone as well as belinostat, both of which are in last stage development. It also has a long line-up of drug candidates- Apaziquone, which is in the Phase 3 clinical trials.
This is for the non-muscle bladder cancer or NMIBC. This will be in strategic collaborations with other company which are located across the world such as Nippon Kayaku co. Ltd. Additionally; it is being studied for multiple pointers such as Phase II registration trail which are either relapsed or refractory peripheral T-Cell lymphoma or PTCL. Under this strategic collaboration the company continues to provide exceptional services.
Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) has a market capital of $443.30 million. The stock has an infra-day trading average of $6.79 low and $7.30 trading average high.
As Spectrum Pharmaceuticals continues to harbour high hopes for nurturing and developing products which are for hematology as well as oncology it is desired that investors keep faith and continue to allow Spectrum to grow.